Capital International Inc. CA Invests $4.25 Million in Illumina, Inc. (NASDAQ:ILMN)

Capital International Inc. CA acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,817 shares of the life sciences company's stock, valued at approximately $4,252,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new stake in Illumina in the 4th quarter worth approximately $751,000. Van ECK Associates Corp increased its holdings in shares of Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $1,464,000. Allworth Financial LP lifted its position in Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after purchasing an additional 6,263 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Illumina in the 4th quarter valued at about $448,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on ILMN shares. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Canaccord Genuity Group decreased their price target on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Citigroup cut their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Finally, Stephens reiterated an "overweight" rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $138.70.

Illumina Trading Down 3.2 %

Shares of Illumina stock opened at $71.21 on Monday. The firm has a fifty day moving average price of $84.61 and a 200 day moving average price of $120.16. The stock has a market cap of $11.27 billion, a PE ratio of -9.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.